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Divergent effects of flavone acetic acid on established versus developing
tumour blood flow
V. Mahadevan & I.R. Hart
Room 536, Imperial Cancer Research Fund Laboratories, PO Box 123, Lincoln's Inn Fields, London WC2A 3PX, UK.
Summary Flavone Acetic Acid (FAA) exerts much of its effect by reducing tumour blood flow. Previous
studies on FAA-induced changes in blood flow have used established tumours with a functional microvas-
culature. Using radioactive Xenon('33Xe) clearance to monitor local blood flow we show that the effects of
FAA are dependent on the presence of this functional microvasculature with no evidence that FAA inhibits
the actual development of tumour microcirculation. Thus, administration of multiple doses of FAA around
the time of tumour cell injection failed to diminish 4 values of '33Xe (e.g. 4 16 min for FAA vs 14 min for
saline controls at 10 days) or to affect tumour volumes (5.55 ± 0.06 cm3 in FAA-treated animals vs
5.7 ± 1.3 cm3 in controls at 25 days). In marked contrast a single dose of FAA (200 mg kg-' body weight) 2
weeks after tumour cell injection dramatically extended 14 times (47 min for FAA vs 7 min for controls;
P <0.001) and significantly reduced tumour burden. This effect is specific for tumour microvasculature and is
not directed simply at new vessels since a similar treatment of animals with implanted-sponge-induced
granulation tissue had no effect on t times (6.8 ± 1.1 min for FAA at 200 mg kg-' vs 7.2 ± 1.0 min for
saline-treated controls).
Flavone Acetic Acid (FAA) is a synthetic flavonoid com-
pound with potent activity against a variety of transplantable
murine tumours including many which are resistant to con-
ventional cytotoxic drugs (Corbett et al., 1986; Plowman et
al., 1986; Bibby et al., 1988a). FAA possesses several features
unusual for an anticancer agent. Thus FAA's activity appears
to be confined to tumours growing subcutaneously (s.c.) as
solid lesions; its effect on tumour cells in culture or against
leukaemia models being minimal (Bibby et al., 1987; Finlay
et al., 1988; Plowman et al., 1986). These characteristics,
coupled with a toxicity profile unlike that of most anti-
neoplastic drugs (Zaharko et al., 1986), suggest that the drug
may have an indirect mode of action.
A possible way whereby FAA might exert its anti-
neoplastic effects is via interruption of the tumour blood
supply. A number of authors, using techniques as varied as
magnetic resonance spectroscopy, dye perfusion and point-
counting of vascular channels, have shown that FAA
administration rapidly effects a dramatic reduction in tumour
blood flow (Evelhoch et al., 1988; Bibby et al., 1989a; Zwi et
al., 1989). Most recently, by means of a radioactive-tracer
clearance assay, we have confirmed this inhibition of tumour
blood flow by FAA and provided evidence that tumour
necrosis factor cz (TNFx) is responsible for this effect
(Mahadevan et al., 1990).
For a given tumour, FAA appears to be less effective
against early stage disease than against its more advanced,
better established counterpart (Bibby et al., 1988b). Certainly
the studies on blood flow inhibition cited above were con-
ducted on overt, palpable tumours which possess a functional
microvasculature (Folkman & Cotran, 1976). We are
unaware of any studies on the effects of FAA on the early
development of tumour microcirculation. Accordingly the
present study, using the clearance of locally-injected '33Xe as
an indication of blood flow (Mahadevan et al., 1989, 1990),
was undertaken to examine the possible effects of FAA on
this early stage of neoplastic growth. Protamine, an arginine-
rich basic protein which is capable of inhibiting tumour
neovascularisation (Folkman, 1985; Taylor & Folkman,
1982), was used as a positive control. We show here that the
inhibition of tumour blood flow achieved by FAA adminis-
tration depends on an established tumour microvasculature
with no evidence that the drug inhibits new vessel formation.
Materials and methods
Animals
Young adult male Balb/c mice (weighing 24-28 g), used in
all experiments, were obtained from the Imperial Cancer
Research Fund animal breeding unit, Clare Hall
Laboratories, South Mimms, Herts, UK. Animals were
housed individually in plastic cages in an air-conditioned
room; food and water were available ad libitum and a 12 h
light/dark schedule was maintained. All animal procedures
were carried out under a Project Licence approved by the
Home Office, London, UK.
Chemicals and reagents
Radioactive Xenon ('33Xe) in sterile physiologic saline
(specific activity 370 MBq in 3 ml) was purchased from
Amersham International, Aylesbury, UK.
Clinically formulated FAA (LIPHA, Lyons, France), sup-
plied as a lyophilised powder, was a generous gift from Dr
J.A. Double, Clinical Oncology Unit, University of Bradford,
UK.
Salmon Protamine sulphate was bought from Calbiochem,
Nottingham, UK. Immediately prior to administration, the
required doses of Protamine or FAA were dissolved in sterile
physiologic saline (0.1 ml 10g-' body weight of animal).
Technique ofsponge implantation
Circular, polyether polyurethane sponge discs of 1.25 cm
diameter x 0.6 cm thickness (Vitafoam Ltd, Manchester,
UK) were sterilised by autoclaving prior to use. Mice were
anaesthetised by the intramuscular injection of Hypnorm
(0.315mgml-' of Fentanyl Citrate and O0mgml
' of
Fluanisone; Janssen Pharmaceuticals) and Hypnovel
(5 mg ml-1 of Midazolam Hydrochloride; Roche), each at a
dose of 0.5 ml kg-' of body weight.
A 1 cm dorsal, vertical, midline skin incision was made
aseptically immediately proximal to the base of the tail and a
dorsal subcutaneous pouch was fashioned 4- 5 cm cephalad
to the incision by gentle, blunt dissection. A sponge disc was
then introduced through the incision and placed flat in this
subcutaneous pouch. The skin incision was closed with two
interrupted 5-0 silk sutures and the animal allowed to
recover.
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Tumour establishment
Colon 26 cells (Tsuro et al., 1983) were grown as monolayers
in Dulbecco's modification of Eagle's essential medium
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(DMEM) supplemented with 10% foetal calf serum (FCS)
and 1% L-glutamine. Cultures were incubated at 37°C in an
humidified atmosphere of 95% air and 5% CO2. Cells were
detached from tissue culture flasks with 0.1% Trypsin/
0.5 mM EDTA. The cell suspension was washed twice in
phosphate buffered saline (PBS) and resuspended to the ap-
propriate concentration in PBS.
Initial experiments established that an inoculum of 1 x 105
to 1 x 106 cells in 100pl PBS injected into the sponge 3 to 4
days post sponge implantation gave a 100% tumour take.
The tumours were palpable between 12 and 14 days follow-
ing cell injection.
Bloodflow measurement
Blood flow measurement was performed as described
previously (Mahadevan et al., 1989, 1990). Tenfl of '33Xe
solution in physiologic saline were injected into the centre of
the implanted sponge and the washout of radioactivity was
monitored at intervals of 1 min for 10 min. The counts were
analysed by a Macintosh-Apple computer programme to
derive the T1 for t33Xe clearance from the exponential curve
fit.
Estimation of133Xe clearancefrom sponge implantsfollowing
tumour cell inoculation
Sterile sponges were implanted in 20 animals. On day 3
post-implantation, (a) seven animals received injections into
the sponge, each of I x 106 Colon 26 cells in 100IlI of PBS,
(b) a further seven animals each received 1 x 105 Colon 26
cells in 100tLI of PBS, and (c) the remaining six animals
(control group) were each injected with 100 jl of PBS into
the sponge.
Clearance of '33Xe from implanted sponges was measured
on days 4, 6, 11 and 15 post-tumour cell injection.
Protamine or FAA treatment
To monitor the effects of protamine and FAA on the
development of tumour vascularisation sponges were
implanted into 15 animals. Three days after sponge implanta-
tion each animal was injected with 1 x 106 Colon 26 cells in
100 gil of PBS into the centre of the sponge and the mice
were assigned arbitrarily to three groups (n = 5 per group).
On the next four successive days animals in Group 1
received i.p. injection of FAA, 150 mgkg-' day-'; animals in
Group 2 received i.p. injections ofprotamine, 50 mgkg-' day-'
and control animals in Group 3 received i.p. injections of
similar volumes of saline diluent. Blood flow was measured 3,
6 and 10 days after completion of drug treatment.
The effect of FAA on blood flow of established tumours
was assessed by implanting sponges into 20 animals and
establishing tumours as detailed above. Fourteen days after
cell injection, when all animals had palpable tumours, ten
animals received a single i.p. injection i.p. of FAA
(200 mg kg-') while ten animals were injected i.p. with a
similar volume of saline diluent. Blood flow was assessed on
days 1 and 2 post-di ig injection.
Measurement oftumour volume
Calipers were used to measure the tumours in two dimen-
sions and volumes were calculated from the formula a x b
a
where 'a' and 'b' are the minor and major dimensions respec-
tively (Bibby et al., 1988a).
Bloodflow in non tumour-bearing sponges after FAA
administration
Fifteen animals received sponge implants. Twenty eight days
later animals in Group 1 (n = 5) received a single i.p. injec-
tion of FAA at 200 mg kg-', animals in Group 2 (n = 5)
received a single i.p. injection of FAA at 250 mg kg' and
animals in Group 3 (n = 5) were injected with saline diluent.
Blood flow measurements were recorded 4 h post drug injec-
tion.
Statistical evaluation
All statistical comparisons were made using Student's t-test.
Results
Effect oftumour development on bloodflow
The effects of tumour growth on '33Xe clearance are illus-
trated in Figure 1. Developing tumour, whether initiated by
the injection of 1 x 105 or 1 x 106 cells, caused a significant
reduction in mean T1 such that 7 days after sponge implanta-
tion (4 days after cell injection) the T1 was 14-15 min com-
pared with 27 min in the control sponges, while on day 14
post-sponge implantation the respective values were 8 min
and 21min (P<0.01).
Effect ofFAA and Protamine Treatment
Figure 2 depicts the effect of FAA on tumour blood flow
depending on whether it was delivered 'early' or 'late' in
tumour development. Four consecutive daily injections of
FAA initiated 1 day after the implantation of the neoplastic
cells had no significant effect on '33Xe clearance times from
the developing tumour when compared to saline treated con-
trols (e.g. Tt at 10 days post sponge implantation was 16 min
for FAA vs 14 min for saline-treated sponges). By com-
parison a single injection of FAA on day 17 after sponge
implantation, and 14 days after tumour cell injection,
resulted 1 day later in a highly significant (P .0.001) pro-
longation of T1 from 7 min for control animals to 47 min for
FAA treated animals (Figure 2).
In contrast to the lack of effect manifested by multiple
injections of FAA early in tumour growth Protamine given
at the same points in time caused a signficant extension of T1
times. Thus on days 10 and 13 post-sponge implantation
protamine-treated animals showed mean T1 values of
27.5 ± 5.3 min and 22.8 ± 2.7 min which differed significantly
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Figure 1 Clearance of "'XE from sponges in absence and
presence of tumour. Each point for the non-tumour bearing
sponges (0) was derived from six individual animals; vertical
bars indicate standard errors about the mean. Tumours were
initiated by the intrasponge injection of I x 106 (U) or I x 10'
(A) cells (n = 7/group). Since animals had to be killed by day 18
post sponge implantation, owing to tumour burden, blood flow
estimates were not possible past this time in these groups. Arrow
indicates day of tumour cell injection.FLAVONE ACETIC ACID AND TUMOUR NEOVASCULARISATION 891
60 -
CD
'- 50-
m
C 40-
0
c
x
o 30-
E
20-
a 10-
n
,~
V I-
I I . 1- r t- .I . I . I . I . I
0 2 4 6 8 10 12 14 16 18 20
Days post sponge implantation
Figure 2 Effect of FAA and Protamine on development of
tumur blood flow. FAA was administered either at an early stage
of tumour development (O) or a late stage of tumour develop-
ment (A) and compared with corresponding saline injected con-
trols (0) and (A) respectively, or with animals which had been
injected with protamine (0). Data points on the graph represent
mean Tt values obtained form at least five animals; vertical bars
represent standard errors about the mean. Day of tumour cell
injection is indicated by (A). Vertical arrows represent either the
days of FAA or protamine administration in the multiple dose
schedule (+) or the day of a single administration of FAA (t+t).
from corresponding control values at levels of P <0.05 and
P <0.01 respectively.
The effect of administration of FAA or protamine early in
the course of tumour growth on subsequent tumour volume
is presented in Table I. While the mean tumour volumes of
FAA-treated animals were always less than those of the
saline-treated control group these differences were not
significant. Similarly the volumes recorded for the protamine
treated group were also less than the control group values
and, at 21 days post sponge implantation, this difference was
significant (P <0.05) (Table I).
Effect ofFAA on vascularised non-tumour bearing sponges
The results of this experiment are presented in Table II. The
mean Tt values obtained for the two groups injected with
FAA were not different from the Tt values recorded for the
control group.
Discussion
We previously have used the '33Xe clearance technique as the
basis for developing a dynamic assessment of blood flow
(Mahadevan et al., 1989) and have shown, using this assay,
that FAA acts to shut down tumour vascularity via the
effects of TNFx (Mahadevan et al., 1990).
Using this technique we now show that the effect of FAA
is dependent on an established microvasculature within the
Table II Effect of i.p. FAA on the clearance of '33XE from
vascularised, non tumour-bearing sponges
Mean Tt (min) ± s.e.m. (n)
Treatment at 4 h post injection
FAA (200mgkg-') 6.8± 1.1
FAA (250mg kg-') 7.0± 1.0
Saline 7.2 ± 1.0
Animals (five per group) were injected with the appropriate agent
28 days after sponge implantation as detailed in the text.
neoplasm. Thus FAA given prior to the development of
vascularisation brought about no prolongation of Tt times
(Figure 2) nor did it retard tumour growth (Table I). In
contrast to these results protamine, which has been shown to
be capable of inhibiting the angiogenic response and thereby
limiting tumour growth (Taylor & Folkman, 1982; Folkman,
1985), brought about significant inhibition of tumour blood
flow development, and retarded tumour growth (Figure 2,
Table I).
By 18 days post sponge implantation, at a time when full
vascularisation of the sponge/tumour had been achieved
(Figure 1), a single dose of FAA produced a highly
significant reduction in '33Xe clearance compared with con-
trols (Figure 2). This inhibition of blood flow was persistent
even up to 10 days after drug administration (data not
shown). In our previous report we showed that these reduc-
tions in vascular flow were associated with a drastic limita-
tion in the size of the treated tumours (Mahadevan et al.,
1990).
It seems clear from these experiments that the efficacy of
FAA in acting against a sensitive tumour is dependent upon
there already being an established microvasculature. Cer-
tainly this could account for the observations that FAA is
more effective against late stage disease (Bibby et al., 1988b)
and help to explain the variation in response to FAA shown
by tumours in distinct anatomical locations (Bibby et al.,
1989b; Finlay et al., 1988). Interestingly the age, or the
development, of the microvasculature per se is not the sole
determinant in regulating FAA activity. Thus when fully
vascularised sponges, showing similar T1 values to those
observed in established tumours, were utilised FAA had no
effect on blood flow. Since the effects of FAA are mediated,
in part at least, via the cytokine TNFa (Smith et al., 1987;
Mace et al., 1990; Mahadevan et al., 1990) it may be that
differences in either the production of or the response to, this
molecule underlie the divergent response.
The major source of TNFx is the macrophage (Le &
Vilcek, 1987). TNFa is a plurifunctional protein with impor-
tant biological effects on a variety of target cell types, includ-
ing the vascular endothelium (Le & Vilcek, 1987). TNFx
induces endothelial cells to elaborate a tissue factor-like pro-
coagulant, and to suppress an essential anti-coagulant co-
factor synthesised by endothelial cells (Fajardo, 1989),
thereby causing intravascular thrombosis (Fajardo, 1989).
Thrombotic occlusion of the vascular bed is believed to be
the mechanism underlying TNFa-induced haemorrhagic ne-
crosis of tumours (Smith et al., 1987; Nawroth et al., 1988).
In support of this hypothesis, Nawroth et al. (1988) showed
that tumour-bearing mice anticoagulated with coumarin,
exhibited significantly less tumour necrosis in response to
Table I Effect of FAA and protamine on tumour volume
Days Post Mean Tumour Volume (cm3) ± s.e.m.
Sponge implantation Protaminea FAAa Salinea (Control)
17 0.9 0.2 (5) 1.4 ±0.2 (5) 1.7 0.4 (5)
21 1.9 ± 0.2b (5) 2.8 ± 0.4 (5) 3.8 ± 0.8 (5)
25 3.7 0.7 (5) 5.55±0.6 (5) 5.7± 1.3 (5)
aAnimals were injected with the appropriate agent on four successive days
after the implantation of tumour cells as detailed in Materials and methods.
Numbers in brackets represent individual animals monitored. bSignificantly
different from saline control values (P.0.05) by Student's t-test.
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TNFa when compared with non-anticoagulated control
animals.
It has been shown that some tumours may be composed of
a large percentage of macrophages, up to 65% for example
(Russell et al., 1980). The granulation tissue occupying the
implanted sponge may not possess the same large
macrophage content as is present in the Colon 26 tumour.
Accordingly, the divergent responses to FAA seen between
tumour-bearing and non tumour-bearing sponges (Figure 2,
Table II) may reflect variation in levels of local TNFa prod-
uction as a consequence of cellular composition. Alterna-
tively, it may be that levels of TNFx production are
comparable, but that the responses of tumour vessels and
normal vessels are different. In this context, it is interesting
to note that Nawroth et al. (1988) found that the vascular
bed in a murine fibrosarcoma, but not adjacent normal
microvasculature, was susceptible to the thrombogenic effect
of systemically-administered TNFa. These authors showed
also that a soluble factor derived from the fibrosarcoma cells
in culture, and devoid of intrinsic procoagulant activity,
potentiated significantly the induction of endothelial tissue
factor by TNFa (Nawroth et al., 1988). Recently Murray et
al. (1989) observed that FAA activated the process of
coagulation both in tumour-bearing and non-tumour-bearing
mice. However, the intensity of this effect was greater in the
tumour-bearing animals. Furthermore, the transient nature
of the coagulopathy in non-tumour bearing animals con-
trasted sharply with the prolonged effects on coagulation in
animals with tumours (Murray et al., 1989).
Whatever the basis of the observed response it is clear
from our studies that FAA does not inhibit the development
of tumour blood vessels but acts against established tumour,
but not normal, microvasculature.
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